Boehringer Ingelheim News
-
Roche Holding AG, the world’s biggest maker of cancer drugs, won U.S. approval to sell a gene mutation test that can help doctors pinpoint patients’ likelihood to respond to a popular treatment for lung cancer.
-
GlaxoSmithKline Plc and Theravance Inc. won U.S. approval of their once-daily drug Breo Ellipta to treat a lung disorder that is the third-leading cause of death.
-
By the time Pfizer Inc., Johnson and Johnson, Elan Corp. and Eli Lilly & Co. announced their experimental medicines had shown limited benefit for Alzheimer’s patients in late-stage testing, the industry and academia had spent more than $30 billion researching amyloid plaque in the brain. Now they are working together to prevent such failures.
-
Celltrion Inc. dropped a late-stage trial of a biosimilar version of Roche Holding AG’s best-selling Rituxan drug, potentially benefiting competitors such as Boehringer Ingelheim GmbH and Novartis AG.
-
Bayer AG and Amgen Inc. are among drugmakers who may face price cuts as a German agency begins a broader review of the costs and benefits of medicines already on the market.
-
Asian stocks fell this week, retreating from a 20-month high, as mining companies declined after reports showed recovery in the Chinese and U.S. economies may be stalling.
-
Asian stocks rose, paring this week’s losses, as Taiwan Semiconductor Manufacturing Co. led technology shares higher and mining companies rebounded.
-
GlaxoSmithKline Plc and Theravance Inc.’s Breo Ellipta should be approved to treat a lung disorder that is the third-leading cause of death in the U.S., advisers to the Food and Drug Administration said.
-
Theravance Inc. surged the most in a year after a staff report by U.S. regulators showed the once- daily lung disease treatment the company is developing with GlaxoSmithKline Plc may be able to win approval.
-
Boehringer Ingelheim GmbH Chairman Andreas Barner may use product deals and regional acquisitions to fuel growth as the world’s largest family-owned drugmaker faces competition from lower-priced generics.
|
|
Boehringer Ingelheim Photos
Most Popular on Bloomberg
|
|
Boehringer Ingelheim Videos
|
|
Rate this Page